Professor Jennifer Green
Endocrinology
Jennifer Green is a professor of medicine and a faculty member of the Duke Clinical Research Institute (DCRI). Her research has focused upon strategies to treat diabetes and reduce the risk of cardiovascular, kidney and other diabetes-related complications. Her work with the DCRI has included protocol development, oversight of adjudication committees, and clinical and operational leadership for several large, international trials designed to determine the cardiovascular effects of glucose-lowering medications (TECOS, EXSCEL, and Harmony Outcomes).
She was also part of the multidisciplinary leadership team for COORDINATE-Diabetes, a trial which was successful in increasing delivery of guideline-based therapies to patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) who received care in cardiology clinics across the US. She is now leading an innovative, centralised study of an intervention to reduce the risk of future diabetic foot ulceration, which will be conducted using an electronic health record-linked software platform developed by a Duke faculty member.
Professor Green has concluded three years of service as a member of the American Diabetes Association’s (ADA) Professional Practice Committee, which publishes the organisation’s annual Standards of Care in Diabetes.
She is now a member of the ADA-EASD (European Association for the Study of Diabetes) writing group which recently revised a joint consensus statement on the management of hyperglycemia in T2D.
PP-PF-OTH-GB-0085 | December 2024
Jennifer Green is a professor of medicine and a faculty member of the Duke Clinical Research Institute (DCRI). Her research has focused upon strategies to treat diabetes and reduce the risk of cardiovascular, kidney and other diabetes-related complications. Her work with the DCRI has included protocol development, oversight of adjudication committees, and clinical and operational leadership for several large, international trials designed to determine the cardiovascular effects of glucose-lowering medications (TECOS, EXSCEL, and Harmony Outcomes).
She was also part of the multidisciplinary leadership team for COORDINATE-Diabetes, a trial which was successful in increasing delivery of guideline-based therapies to patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) who received care in cardiology clinics across the US. She is now leading an innovative, centralised study of an intervention to reduce the risk of future diabetic foot ulceration, which will be conducted using an electronic health record-linked software platform developed by a Duke faculty member.
Professor Green has concluded three years of service as a member of the American Diabetes Association’s (ADA) Professional Practice Committee, which publishes the organisation’s annual Standards of Care in Diabetes.
She is now a member of the ADA-EASD (European Association for the Study of Diabetes) writing group which recently revised a joint consensus statement on the management of hyperglycemia in T2D.
PP-PF-OTH-GB-0085 | December 2024